EP3539034A1 - Cna-guided care for improving clinical outcomes and decreasing total cost of care - Google Patents
Cna-guided care for improving clinical outcomes and decreasing total cost of careInfo
- Publication number
- EP3539034A1 EP3539034A1 EP17869390.9A EP17869390A EP3539034A1 EP 3539034 A1 EP3539034 A1 EP 3539034A1 EP 17869390 A EP17869390 A EP 17869390A EP 3539034 A1 EP3539034 A1 EP 3539034A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- patient
- care
- clinical outcome
- medical
- cna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003247 decreasing effect Effects 0.000 title claims description 9
- 230000036541 health Effects 0.000 claims abstract description 192
- 238000004458 analytical method Methods 0.000 claims abstract description 155
- 238000011282 treatment Methods 0.000 claims abstract description 109
- 238000004891 communication Methods 0.000 claims abstract description 83
- 201000010099 disease Diseases 0.000 claims abstract description 68
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 51
- 230000003542 behavioural effect Effects 0.000 claims abstract description 43
- 230000004044 response Effects 0.000 claims abstract description 38
- 230000002411 adverse Effects 0.000 claims abstract description 31
- 230000008901 benefit Effects 0.000 claims abstract description 26
- 230000002829 reductive effect Effects 0.000 claims abstract description 21
- 238000011156 evaluation Methods 0.000 claims abstract description 20
- 230000003993 interaction Effects 0.000 claims abstract description 14
- 238000004590 computer program Methods 0.000 claims abstract description 12
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 11
- 238000005192 partition Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 59
- 238000012360 testing method Methods 0.000 claims description 54
- 238000002560 therapeutic procedure Methods 0.000 claims description 49
- 231100000419 toxicity Toxicity 0.000 claims description 44
- 230000001988 toxicity Effects 0.000 claims description 44
- 230000004083 survival effect Effects 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 41
- 238000003745 diagnosis Methods 0.000 claims description 39
- 238000012545 processing Methods 0.000 claims description 27
- 230000008859 change Effects 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 11
- 230000034994 death Effects 0.000 claims description 10
- 238000003384 imaging method Methods 0.000 claims description 10
- 238000007726 management method Methods 0.000 claims description 10
- 241000208125 Nicotiana Species 0.000 claims description 8
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000000090 biomarker Substances 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 238000004393 prognosis Methods 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 230000005540 biological transmission Effects 0.000 claims description 6
- 230000000007 visual effect Effects 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 description 26
- 238000010586 diagram Methods 0.000 description 23
- 206010006187 Breast cancer Diseases 0.000 description 18
- 208000026310 Breast neoplasm Diseases 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 18
- 230000006870 function Effects 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 10
- 208000029742 colonic neoplasm Diseases 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 8
- 230000002085 persistent effect Effects 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 238000013475 authorization Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 101150105104 Kras gene Proteins 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000011548 physical evaluation Methods 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- APTZNLHMIGJTEW-UHFFFAOYSA-N pyraflufen-ethyl Chemical compound C1=C(Cl)C(OCC(=O)OCC)=CC(C=2C(=C(OC(F)F)N(C)N=2)Cl)=C1F APTZNLHMIGJTEW-UHFFFAOYSA-N 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101000928724 Pseudomonas putida 4-cresol dehydrogenase [hydroxylating] flavoprotein subunit Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000003490 calendering Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/10—Office automation; Time management
- G06Q10/109—Time management, e.g. calendars, reminders, meetings or time accounting
- G06Q10/1093—Calendar-based scheduling for persons or groups
- G06Q10/1095—Meeting or appointment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/40—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Definitions
- the present disclosure relates to CNA-guided care for improving clinical outcomes at the specific patient level and for decreasing total cost of care at the population level.
- a clinical outcome tracking and analysis (COTA) module is a tool to, for example, enable medical professionals and/or other users to practice better medicine, better manage and locate specific information associated with a disease and/or patient, and facilitate improved control of cost.
- the parameters of clinical outcome tracking and analysis include sorting, outcome tracking, Eastern Cooperative Oncology Group (ECOG) performance status;
- ECOG Eastern Cooperative Oncology Group
- a method and system include the COTA module that receives, from a client device operated by a user, one or more parameters to sort a plurality of data records, and, in response to the receiving, sorts the data records based on the received parameters.
- a nodal address, indicating one or more variables, is applied to the sorted set of patient medical records to determine a clinically relevant set of patient medical records as the sorted set of patient medical records satisfying the one or more variables.
- the COTA module then analyzes the clinically relevant set of patient medical records and communicates at least a portion of the classified and sorted data records and the updated data records to a client device for display.
- Each data record includes data associated with a disease and data associated with patients currently having the disease or patients who previously had the disease.
- the COTA module can receive the data from an electronic medical record (EMR), from a user, from a medical professional, from an expert, or from any other source.
- EMR electronic medical record
- the COTA module can enable the user to perform various analyses on one or more of the data records.
- the COTA module can enable a comparison of data or of tracked outcomes between patients can identify a specific patient as a candidate for a specific treatment or drug, can communicate an analysis tool to the client device to facilitate analysis of, for instance, the classified and sorted data records or to enable comparison of Kaplan Meier curves, and can determine, based on the tracking, whether a specific doctor associated with a patient is treating the patient in accordance with treatment techniques of other doctors treating other (similar) patients.
- the COTA module may also transmit an alert to the client device upon the occurrence of a trigger.
- a trigger may be, for example, at diagnosis, at progression, at dose change, at drug change, at toxicity, when trending towards variance from a desired outcome, and/or at a specific time.
- the COTA module tracks consequences of treatment choices and reports on outcomes associated with the use of COTA Nodal Addresses (CNAs). It accounts for biological variance upfront by grouping patients in a patient population, which effectively removes biological variance as a factor in value of care, leaving treatment variance as a predominant factor in treatment outcome.
- the COTA module receives, collects, and records personal health information from each patient in the patient population in a database, and sorts the personal health information. Like personal health information is classified, and types of patients in the patient population are grouped based on the personal health information by generating and assigning a plurality of nodal addresses within the COTA module.
- Each CNA is represented as a discrete punctuated string of digits comprising a prefix, a middle, and a suffix that represent a set of preselected variables that partition the sorted and classified information into a clinically relevant set of health information.
- a plurality of CNAs reduces trillions of possible permutations to a reduced number of clinically meaningful permutations based on the discrete punctuated string of digits representing each nodal address that enable analysis of first behavioral and then consequent clinical and cost outcome variance from an ideal value, expressed as best clinical outcome at lowest possible cost, in a requisite time needed to alert for necessary care and avoidance of unnecessary care, thereby increasing the value of care, meaning better clinical outcomes at a lowest possible cost; reduce processing requirements and time for processing to make real-time monitoring of medical provider performance efficient based on the discrete punctuated string of digits representing each nodal address and based on the reduction in permutations; and enable prediction of key points in time at which behavioral variance is likely to occur and interrupting treatment flow to avoid over-
- the described invention provides CNA-guided care.
- CNA-guided care has two faces, which together, through the triad of a health care provider, a payer, and the patient suffering from a disease, enables value based care delivery in the United States through the application of CNAs.
- the first face comprises interactions between a medical care provider, a computer containing a processor comprising a first COTA module, a first client device comprising a second COTA module that is communicatively linked to the first COTA via a network, and a payer. It enables a payer to transmit via the first client device comprising a second COTA module communicatively linked to the first COTA module of the processor, a communication over the network to the processor identifying a health care service under consideration for a patient whose health plan benefits cover the service;
- the first COTA module can transmit to the second COTA module information comprising (i) the clinical outcome data for each CNA, (ii) the adverse variance data for each medical provider at each CNA including both necessary care that is absent and unnecessary care contributing to the medical care provider's adverse variance for patients at each nodal address at key points in time during treatment; (iii) a cost report comprising cost data in real time for treating each patient in the patient population assigned to the CNA; and (iv) graphic analyses correlating one or more of (1) cost of care to clinical outcome; (2) incidence and severity of toxicity to cost of care and clinical outcome of care; and (3) therapy and quality of life.
- the payer when the payer can establish at key points in time, (a) that the medical service is an appropriate delivery or level of service, considering potential benefits and harms to the patient; (b) that the medical service is effective in improving health outcome by improving clinical outcomes and reducing total cost of care; that the service is cost-effective for the medical condition being treated and the clinical outcome, compared to alternative health interventions or no intervention; and that the service follows generally accepted medical practice, the payer can approve payment to the medical care provider for the medical service for the patient.
- this enabling tool can be effective to eliminate precertification for testing, diagnostics, and therapeutic choices; eliminate prior authorization; and eliminate the need for referrals. From the medical care provider's vantage point, it reduces the time necessary to pay the provider for healthcare. Accordingly, the enabling tool enables healthcare to optimize fee for service based reimbursement and to move from fee for services to risk-based care reimbursement (for example by bundling services),
- the second face of CNA-guided healthcare comprises interactions between the computer containing the processor comprising the first COTA module, a second client device comprising a third COTA module that is communicatively linked to the first COTA module via a network, and the patient.
- CNA-guided healthcare Through a series of communications between the first COTA module and the patient, CNA-guided healthcare, first, provides the patient with information sufficient for the patient to get a complete medical evaluation of his/her condition and for the first COTA module to assign a CNA to the patient; second, using the CNA, it shows the patient treatment options based on geography, clinical outcome, cost and other patient-set criteria that enable the patient to select care optimized to avoid adverse variance; third it shows the patient health care providers in his/her area who follow CNA guided care that have the best outcomes at an acceptable cost of care.
- the described invention provides a method, a system and non-transitory computer readable medium storing computer program instructions that when executed on a processor cause the first COTA module to perform operations that use CNA-guided care to improve clinical outcomes at a specific patient level and to decrease total cost of care at the population level.
- the described invention provides a method for improving clinical outcomes at a specific patient level and for decreasing total cost of care at a population level comprising: A. interactions between a medical care provider, a computer containing a processor comprising a first clinical outcome tracking and analysis module, a first client device comprising a second clinical outcome tracking and analysis module that is communicatively linked to the first clinical outcome tracking and analysis module via a network, and a payer; and B interactions between the computer containing the processor comprising a first clinical outcome tracking and analysis module, a second client device comprising a third clinical outcome tracking and analysis module communicatively linked to the first clinical outcome tracking and analysis module via the network, and a patient, the computer containing the processor comprising the first clinical outcome tracking and analysis module executing on the processor comprising the first clinical outcome tracking and analysis module, steps comprising: (a) accounting for biological variance upfront by grouping patients in a patient population, thereby effectively removing biological variance as a factor in value of care, and leaving treatment variance as a predominant factor in treatment
- CNAs Clinical outcome tracking and analysis Nodal Addresses
- the parameters of sorting in (a)(ii) comprise one or more of: sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care; or
- the set of preselected variables in (a)(iii)(l) includes a disease-specific clinical molecular phenotype, wherein the string of digits representing the phenotype is determined based on a directed graph; or
- the key points in time in step (a)(iii)(4) and step (b)(i')(4') include one or more of at diagnosis, at progression, at dose change; at drug change; upon toxicity, and trending towards variance from desired outcome; or
- the one or more bundles of predetermined patient care services provides a predetermined course of treatment, cost certainty for treatment of the condition, or both.
- the method further comprises identifying the best clinical outcome at the lowest cost of care at the CNA by ranking both clinical outcome and cost of care in the one or more bundles of predetermined patient care services.
- visual classification of the list of medical professionals by clinical outcome comprises: (a) green signifying a better than average clinical outcome; (b) yellow signifying an average clinical outcome; and (c) red signifying a poorer than average clinical outcome.
- the method further comprises, with permission from the patient and the selected medical professional: transmitting the personal health information of the patient from the first clinical outcome tracking and analysis module, to a computing device comprising a fourth clinical outcome tracking and analysis module at the selected medical professional's office.
- the behavioral variance data for each medical provider at each CNA in (c) includes both necessary care that is absent and unnecessary care contributing to the medical care provider's adverse variance for patients at each CNA at the key points in time during treatment.
- the method further comprises in step (d) indicating that the service is for the purpose of diagnosing or treating a medical condition.
- the cost report contains: a comparison between physician and average cost per revenue; or hospital contribution margin in dollars and percent comparisons; or hospital average revenue per patient; or hospital average cost per patient; or average cost per case for each physician, weight peer average; or average cost of imaging, lab work, evaluation and management; or pharmaceuticals, medical supplies and other expenses for each physician; or a combination thereof.
- the variables selected by the payer include variables that identify certain attributes of the personal health information as a desired set of characteristics; one or more attributes added by the payer to the personal health information to identify the personal health information of each patient as being on an equal level of importance to other health information in the patient population database, or both.
- the described invention provides a system for improving clinical outcomes at a specific patient level and for decreasing total cost of care at a population level comprising: (A) a processor of a computer server comprising: a database comprising personal health information and data for a population of human subjects; a first clinical outcome tracking and analysis module communicatively linked to the database and a network; and a memory to store computer program instructions; (B) a first client device comprising a processing unit; a memory, and a second clinical outcome tracking and analysis module communicatively linked to the first clinical outcome tracking and analysis module of the processor of the computer server; and (C) a second client device comprising a processing unit, a memory, and a third clinical outcome tracking and analysis module communicatively linked to the first clinical outcome tracking and analysis module of the processor of the computer server; the computer program instructions of (A), when executed on the processor causing the first clinical outcome tracking and analysis module to perform operations comprising: (a) accounting for biological variance upfront by grouping patients in a patient population,
- the parameters of sorting in (a) comprise one or more of: sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care; or (b) the set of preselected variables in
- step (a)(iii)(l) includes a disease-specific clinical molecular phenotype, wherein the string of digits representing the phenotype is determined based on a directed graph; or (c) the key points in time in step (a)(iii)(4) and step (b)(i')(4') include one or more of at diagnosis, at progression, at dose change; at drug change; upon toxicity, and trending towards variance from desired outcome; or (d) the correlating cost of care to clinical outcome step in (b)(l')(4') comprises correlating one or more of incidence of toxicity, severity of toxicity; therapy; and quality of life to cost of care and outcome of care; or (e) the receiving of the transmission from the client device in (b) or (c) is via a human user or a technical process; or (f) the assigned CNA in (c)(iii")(b")(l") is associated with one or more bundles of predetermined patient care services for treatment of the condition; or (g)
- the one or more bundles of predetermined patient care services provides a predetermined course of treatment, cost certainty for treatment of the condition, or both.
- the system further comprises identifying the best clinical outcome at the lowest cost of care at the assigned CNA by ranking both clinical outcome and cost of care in the one or more bundles of predetermined patient care services.
- the visual classification of the list of medical professionals by clinical outcome comprises: (a) green signifying a better than average clinical outcome; (b) yellow signifying an average clinical outcome; and (c) red signifying a poorer than average clinical outcome.
- the system further comprises, with permission from the patient and the selected medical professional, transmitting the personal health information of the patient from the first clinical outcome tracking and analysis module, to a computing device comprising a fourth clinical outcome tracking and analysis module at the selected medical professional's office.
- the behavioral variance data for each medical provider at each CNA in (c) includes both necessary care that is absent and unnecessary care contributing to the medical care provider's adverse variance for patients at each CNA at the key points in time during treatment.
- system further comprises further comprises indicating that the service is for the purpose of diagnosing or treating a medical condition.
- the cost report contains: a comparison between physician and average cost per revenue; or hospital contribution margin in dollars and percent comparisons; or hospital average revenue per patient; or hospital average cost per patient; or average cost per case for each physician, weight peer average; or average cost of imaging, lab work, evaluation and management; or pharmaceuticals, medical supplies and other expenses for each physician; or a combination thereof.
- the variables selected by the payer include variables that identify certain attributes of the personal health information as a desired set of characteristics; one or more attributes added by the payer to the personal health information to identify the personal health information of each patient as being on an equal level of importance to other health information in the patient population database, or both.
- the described invention provides a non- transitory computer readable medium storing computer program instructions for facilitating interactions (A) between a medical care provider, a computer containing a processor comprising a first clinical outcome tracking and analysis module, a first client device comprising a second clinical outcome tracking and analysis module
- the parameters of sorting in (a) comprise one or more of: sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care; or (b) the set of preselected variables in
- step (a)(iii)(l) includes a disease-specific clinical molecular phenotype, wherein the string of digits representing the phenotype is determined based on a directed graph; or (c) the key points in time in step (a) (in) (4) and step (b)(i')(4') include one or more of at diagnosis, at progression, at dose change; at drug change; upon toxicity, and trending towards variance from desired outcome; or (d) the correlating cost of care to clinical outcome step in (b)(l')(4') comprises correlating one or more of incidence of toxicity, severity of toxicity; therapy; and quality of life to cost of care and outcome of care; or (e) the receiving of the transmission from the client device in (b) or (c) is via a human user or a technical process; or (f) the assigned CNA in (c)(iii")(b")(l") is associated with one or more bundles of predetermined patient care services for treatment of the condition; or (g) the
- the one or more bundles of predetermined patient care services provides a predetermined course of treatment, cost certainty for treatment of the condition, or both.
- the non-transitory computer readable medium further comprises identifying the best clinical outcome at the lowest cost of care at the assigned CNA by ranking both clinical outcome and cost of care in the one or more bundles of predetermined patient care services.
- the visual classification of the list of medical professionals by clinical outcome comprises: (a) green signifying a better than average clinical outcome; (b) yellow signifying an average clinical outcome; and (c) red signifying a poorer than average clinical outcome.
- the non-transitory computer readable medium further comprises, with permission from the patient and the selected medical professional: transmitting the personal health information of the patient from the first clinical outcome tracking and analysis module, to a computing device comprising a fourth clinical outcome tracking and analysis module at the selected medical professional's office.
- the behavioral variance data for each medical provider at each CNA in (c) includes both necessary care that is absent and unnecessary care contributing to the medical care provider's adverse variance for patients at each CNA at the key points in time during treatment.
- the nontransitory computer readable medium further comprises indicating that the service is for the purpose of diagnosing or treating a medical condition.
- the cost report contains: a comparison between physician and average cost per revenue; or hospital contribution margin in dollars and percent comparisons; or hospital average revenue per patient; or hospital average cost per patient; or average cost per case for each physician, weight peer average; or average cost of imaging, lab work, evaluation and management; or pharmaceuticals, medical supplies and other expenses for each physician; or a combination thereof.
- the variables selected by the payer include variables that identify certain attributes of the personal health information as a desired set of characteristics; one or more attributes added by the payer to the personal health information to identify the personal health information of each patient as being on an equal level of importance to other health information in the patient population database, or both.
- Fig. 1 illustrates a block diagram of an example of some of the pressures in the oncology market and some potential solutions
- Fig. 2 illustrates a block diagram of a server computer communicating with one or more user computers over a network to provide a clinical outcome tracking and analysis (COTA) module to the one or more user computers in accordance with an embodiment of the present disclosure
- COTA clinical outcome tracking and analysis
- Fig. 3 is a block diagram illustrating several functions provided by the COTA module in accordance with an embodiment of the present disclosure
- Fig. 4A is a block diagram illustrating use of the COTA module to sort data associated with colon cancer patients in accordance with an embodiment of the present disclosure
- Fig. 4B is a flow diagram of the COTA module sorting data through specific node creation in accordance with an embodiment of the present disclosure
- Fig. 4C is a block diagram illustrating a directed graph for determining a string of digits representing phenotype characteristics for nodal addressing in accordance with an embodiment of the present disclosure
- Fig. 5A is a flowchart illustrating steps performed by the COTA module in accordance with an embodiment of the present disclosure
- Fig. 5B is a flowchart illustrating steps for enabling a patient diagnosed with a condition to optimize treatment options in accordance with an embodiment of the present disclosure
- Fig. 6 illustrates a flow diagram of the COTA module transmitting alerts in response to triggers in accordance with an embodiment of the present disclosure
- Fig. 7 is a graphical representation illustrating a mobile device organizing received alerts in accordance with an embodiment of the present disclosure
- Fig. 8 shows a graphical representation of incidence of disease by cancer subtype in accordance with an embodiment of the present disclosure
- Fig. 9 is a graphical representation of a search refined by variables input into the COTA module in accordance with an embodiment of the present disclosure
- Fig. 10 shows a listing of a plurality of variables pertinent to a particular disease in accordance with an embodiment of the present disclosure
- Fig. 11 shows a graphical representation including real-time Kaplan Meier curves with confidence intervals for pancreatic cancers in accordance with an embodiment of the present disclosure
- Fig. 12 is a graphical representation showing Kaplan Meier curves by disease progression in accordance with an embodiment of the present disclosure
- Fig. 13 is a graphical representation of real-time benchmarking of outcomes between two parties in accordance with an embodiment of the present disclosure
- Fig. 14 is a graphical representation of a cost report in accordance with an embodiment of the present disclosure.
- FIGs. 15 A and 15B are graphical representations of a treatment interface in accordance with an embodiment of the present disclosure.
- Fig. 16. is a graphical representation of an outcome screen in accordance with an embodiment of the present disclosure
- Fig. 17 is a graphical representation of a treatment details report screen in accordance with an embodiment of the present disclosure
- Fig. 18 is a graphical representation of an analysis screen comparing toxicity and cost in accordance with an embodiment of the present disclosure
- Fig. 19 is a graphical representation of an analysis screen comparing therapy and quality of life in accordance with an embodiment of the present disclosure
- Fig. 20 is a flow diagram of feedback support provided to a medical professional in accordance with an embodiment of the present disclosure
- Figs. 21-23 display embodiments of graphical representations for different diagnosis types in accordance with an embodiment of the present disclosure
- Fig. 24 shows a graphical representation illustrating the COTA module's data generation and sorting for breast oncology - breast cancer from year 2008 to year 2013 histology with invasive ductal carcinoma in accordance with an embodiment of the present disclosure
- Fig. 25 shows a graphical representation illustrating the COTA module's data generation and sorting for breast oncology - breast cancer from year 2008 to year 2013 tumor grade and stage in accordance with an embodiment of the present disclosure
- Fig. 26 shows a graphical representation illustrating the COTA module's data generation and sorting for breast cancer - stage IIB from year 2008 to 2013 in accordance with an embodiment of the present disclosure
- Fig. 27 shows a graphical representation illustrating overall survival outcomes for breast cancer patients in accordance with an embodiment of the present disclosure
- Fig. 28 shows a graphical representation illustrating outcomes for breast cancer - a comparison between two parties in accordance with an embodiment of the present disclosure
- Fig. 29 depicts one example of a schematic diagram illustrating a client device in accordance with an embodiment of the present disclosure
- Fig. 30 is a block diagram illustrating an internal architecture of a computer in accordance with an embodiment of the present disclosure.
- Fig. 31 is a flow chart showing the patient face of CNA-guided care in accordance with an embodiment of the present disclosure for a patient with breast cancer.
- Fig. 32 is a block diagram illustrating the advantages of the two faces of CNA guided care.
- the provider-payer face enables elimination of precertification for testing, diagnostics, and therapeutic choices; elimination of prior authorization and the need for referrals optimizing fee for service based reimbursement and enabling a move from fee for service to risk-based reimbursement.
- the patient face for a patient using CNA guided care does three things: first, it provides information to the patient so the patient gets a complete evaluation of his/her condition (e.g., physical evaluation; laboratory evaluation; imaging, etc.) so that a CNA can be assigned; second, it shows the patient treatment options for the condition that optimize care and reduce risk of adverse variance; and third, it shows the patient the doctor' s in his/her area who follow CNA guided care and have the best outcomes at an acceptable cost of care.
- his/her condition e.g., physical evaluation; laboratory evaluation; imaging, etc.
- the described clinical outcome therapeutic analysis can be used for any clinical condition (e.g., cardiovascular disease, metabolic disease (diabetes), immune mediated diseases (e.g., lupus, rheumatoid arthritis), organ transplantation; neurodegenerative disorders; pulmonary diseases, infectious diseases, hepatic disorders; behavioral health).
- cardiovascular disease e.g., cardiovascular disease, metabolic disease (diabetes), immune mediated diseases (e.g., lupus, rheumatoid arthritis), organ transplantation; neurodegenerative disorders; pulmonary diseases, infectious diseases, hepatic disorders; behavioral health).
- diabetes e.g., diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes, diabetes,
- the reimbursement model in the U.S. will likely change from a fee-for-service model to a value-based payment model.
- the Affordable Care Act has accelerated certain elements of this (e.g., accountable care organizations (ACOs) & patient centered medical home (PCMHs) models for primary care) and there is payer activity towards bundling payments within specialties (e.g. orthopedics).
- ACOs accountable care organizations
- PCMHs patient centered medical home
- the current fee-for-service payment model is likely not sustainable for the government, employers, other payers, and/or for physicians. Many physicians are also finding the economics of a fee-for-service model unsustainable. As indicated above, the government is likely moving towards value-based payment models.
- Oncologists 105 face financial pressures, many cannot continue business with their current models, and many are looking to find new ways of leverage.
- Potential oncologist solutions 110 include aggregating and new payment models, such as bundles.
- Pharmaceutical companies (shown as "Pharma") 115 typically have much or all of their oncology pipeline as highly targeted therapies.
- Possible pharmaceutical solutions 120 include patient identification and changing their business model.
- Health plans 125 typically have an increasing need to "manage" oncology. Also, there are no credible tools or capabilities internally to perform this management. Additionally, medical professionals such as physicians may not buy into the health plans.
- Potential health plan solutions 130 include new payment models (e.g., bundles) and controlling costs.
- Fig. 2 illustrates a block diagram of a server computer 205 (also referred to below as server 205) communicating with a user computer (also referred to herein as client device) 210 and a user computer (also referred to herein as computing device) 230 over network 215 to provide a clinical outcome tracking and analysis (COTA) module 220 to the user computer 210 and/or user computer 230 in accordance with one embodiment.
- Server 205 may generate and/or serve web pages, for example, to be displayed by a browser (not shown) of user computer 210 and/or user computer 230 over network 215 such as the Internet.
- the COTA module 220 is a web page (or is part of a web page) and is therefore accessed by a user of the user computer 210 and/or user computer 230 via a web browser.
- the COTA module 220 is a software application, such as a mobile "app", that can be downloaded to the user computer 210 and/or user computer 230 from the server computer 205.
- the COTA module 220 provides a user interface for enabling the functionality described herein.
- a computing device such as server computer 205, user computer 210, and user computer 230 may be capable of sending or receiving signals, such as via a wired or wireless network, or may be capable of processing or storing signals, such as in memory as physical memory states.
- Devices capable of operating as a server may include, as examples, dedicated rack-mounted servers, desktop computers, laptop computers, set top boxes, integrated devices combining various features, such as two or more features of the foregoing devices, or the like. Servers may vary widely in configuration or capabilities, but generally a server may include one or more central processing units and memory.
- a server may also include one or more mass storage devices, one or more power supplies, one or more wired or wireless network interfaces, one or more input/output interfaces, or one or more operating systems, such as Windows® Server, Mac® OS X®, Unix®, Linux®, FreeBSD®, or the like.
- Server 205 may include a device that includes a configuration to provide content via a network to another device.
- Server 205 may, for example, host a site, such as a social networking site, examples of which may include, without limitation, Flickr®, Twitter®, Facebook®, Linkedln®, or a personal user site (such as a blog, vlog, etc.).
- Server 205 may also host a variety of other sites, including, but not limited to, business sites, educational sites, dictionary sites, encyclopedia sites, wikis, financial sites, government sites, etc.
- Server 205 may further provide a variety of services that include, but are not limited to, web services, third-party services, audio services, video services, email services, instant messaging (EV1) services, SMS services, MMS services, FTP services, voice over IP (VOIP) services, calendaring services, photo services, or the like.
- Examples of content may include text, images, audio, video, or the like, which may be processed in the form of physical signals, such as electrical signals, for example, or may be stored in memory, as physical states, for example.
- Examples of devices that may operate as a server include desktop computers, multiprocessor systems, microprocessor-type or programmable consumer electronics, etc.
- the server 205 hosts or is in communication with a database 240.
- the database 240 may be stored locally or remotely from the server 205.
- the COTA module 220 accesses or searches or sorts the data stored in database 240.
- the COTA module 220 may also retrieve information over network 215 (e.g., from the Internet).
- Database 240 may store patient data or other pertinent medical information.
- the data entered into the database or the COTA module 220 may be from experts in their respective fields (e.g., oncologists with more than 5, 10, 15, 20, 30, etc. years of experience). The data can be entered into the database 240 and/or the COTA module 220 manually or automatically.
- a network may couple devices so that communications may be exchanged, such as between a server and a client device or other types of devices, including between wireless devices coupled via a wireless network, for example.
- a network may also include mass storage, such as network attached storage (NAS), a storage area network (SAN), or other forms of computer or machine readable media, for example.
- a network may include the Internet, one or more local area networks (LANs), one or more wide area networks (WANs), wire-line type connections, wireless type connections, or any combination thereof.
- LANs local area networks
- WANs wide area networks
- wire-line type connections such as may employ differing architectures or may be compliant or compatible with differing protocols, may intemperate within a larger network.
- Various types of devices may, for example, be made available to provide an interoperable capability for differing architectures or protocols.
- a router may provide a link between otherwise separate and independent LANs.
- a communication link or channel may include, for example, analog telephone lines, such as a twisted wire pair, a coaxial cable, full or fractional digital lines including Tl, T2, T3, or T4 type lines, Integrated Services Digital Networks (ISDNs), Digital Subscriber Lines (DSLs), wireless links including satellite links, or other communication links or channels, such as may be known to those skilled in the art.
- analog telephone lines such as a twisted wire pair, a coaxial cable, full or fractional digital lines including Tl, T2, T3, or T4 type lines, Integrated Services Digital Networks (ISDNs), Digital Subscriber Lines (DSLs), wireless links including satellite links, or other communication links or channels, such as may be known to those skilled in the art.
- ISDNs Integrated Services Digital Networks
- DSLs Digital Subscriber Lines
- wireless links including satellite links, or other communication links or channels, such as may be known to those skilled in the art.
- a computing device or other related electronic devices may be remotely coupled to a network, such as via
- a wireless network may couple client devices with a network.
- a wireless network may employ stand-alone ad-hoc networks, mesh networks, Wireless LAN WLAN) networks, cellular networks, or the like.
- a wireless network may further include a system of terminals, gateways, routers, or the like coupled by wireless radio links, or the like, which may move freely, randomly or organize themselves arbitrarily, such that network topology may change, at times even rapidly.
- a wireless network may further employ a plurality of network access technologies, including Long Term Evolution (LTE), WLAN, Wireless Router (WR) mesh, or 2nd, 3rd, or 4th generation (2G, 3G, or 4G) cellular technology, or the like.
- Network access technologies may enable wide area coverage for devices, such as client devices with varying degrees of mobility, for example.
- a network may enable RF or wireless type communication via one or more network access technologies, such as Global System for Mobile communication (GSM), Universal Mobile Telecommunications System (UMTS), General Packet Radio Services (GPRS), Enhanced Data GSM Environment (EDGE), 3GPP Long Term Evolution (LTE), LTE Advanced, Wideband Code Division Multiple Access (WCDMA), Bluetooth, 802.11b/g/n, or the like.
- GSM Global System for Mobile communication
- UMTS Universal Mobile Telecommunications System
- GPRS General Packet Radio Services
- EDGE Enhanced Data GSM Environment
- LTE Long Term Evolution
- LTE Advanced Long Term Evolution
- WCDMA Wideband Code Division Multiple Access
- Bluetooth 802.11b/g/n, or the like.
- the user computer 210 and/or user computer 230 are smartphones. In another embodiment, the user computer 210 and/or user computer 230 are tablets. The user computer 210 and/or user computer 230 can also be a computer, a music player, a set-top box, a smart TV, or any other computing device that can transmit information.
- the COTA module 220 can establish an effective way to manage patients, resulting in better outcomes at controlled costs.
- the COTA module 220 is the connector or interface between third parties and medical professionals (e.g., oncologists).
- the COTA module 220 is an analytic tool that sorts cancers to the highest level of clinical and molecular fidelity. The COTA module 220 then tracks outcomes in real-time, such as overall survival (OS), Progression free survival (PFS), and cost.
- OS overall survival
- PFS Progression free survival
- Overall survival may be a trial endpoint, which is usually expressed as a period of time (survival duration), e.g., in months. Frequently, the median is used so that the trial endpoint can be calculated once 50% of subjects have reached the endpoint.
- An example is disease free survival, which is usually used to analyze the results of the treatment for the localized disease which renders the patient apparently disease free, such as surgery or surgery plus adjuvant therapy. In the disease-free survival, the event is relapse rather than death. The people who relapse are still surviving but they are no longer considered disease-free.
- Progression free survival is the length of time during and after medication or treatment during which the disease being treated (e.g., cancer) does not get worse. It is sometimes used as a metric to study the health of a person with a disease to try to determine how well a new treatment is working.
- the disease being treated e.g., cancer
- real-time means without perceivable delay or information that is delivered immediately after collection or processing. These terms also include a time delay introduced by automated processing (e.g., near real-time).
- the COTA module 220 can alert the user of the user computer 210 and/or user computer 230 (e.g., medical professional) at key moments to provide relevant information.
- the COTA module 220 can also enable communication and collaboration between medical professionals as well as content publishing (e.g., by medical professionals).
- COTA module 220 can enable medical professionals to execute at-risk contracts (e.g., bundled payments) with payers.
- COTA module 220 is described herein with respect to cancer, the COTA module 220 can be utilized advantageously to manage any disease or condition.
- descriptive elements of COTA include sorting, outcome tracking, performance status/quality of life metrics, toxicity to therapy and cost of care.
- Fig. 3 is a block diagram illustrating functions 300 provided by the COTA module 220 in accordance with one embodiment.
- the COTA module 220 performs COTA sorting 310, which identifies patients satisfying one or more parameters.
- Parameters may include, for example, demographic parameters, e.g., sex, age, ethnicity, comorbidities, tobacco use, medical record number, source of insurance, primary care medical professional, referring medical professional, hospital, approved service vendors (e.g., pharmacy), disease specific clinical and molecular phenotype, therapy intent, stage of therapy with respect to progression of disease, and biomarkers.
- the parameters may be a simple indicator (e.g., positive, negative, not accessed), a numerically based parameter (e.g., tumor size), a standards based parameter (e.g., tumor grade), etc.
- the parameters may be received by the COTA module 220 as a user selected input.
- Patients may be sorted 310 at the time of diagnosis to the highest level of clinical and/or molecular fidelity because each patient has different mortality, morbidity, treatments and costs.
- the term "highest level of clinical and/or molecular fidelity" refers to the highest level of patient information available according to the latest scientific and/or medical guidelines as accepted in its pertinent field. For example, where there are, e.g., 10 tests available for lung cancer, results of the 10 tests represent the highest level of fidelity for lung cancer.
- the COTA module 220 may sort patients with lung cancer with any combination of those 10 results.
- the COTA module 220 may include additional scientific and/or medical guidelines as they become accepted in its pertinent field.
- the COTA module 220 collects all information that impacts survival and/or prognosis and/or treatment of a patient based on the latest scientific and/or medical guidelines. [0073] Further, the COTA module 220 performs outcome tracking and analysis 320. The COTA module 220 tracks outcomes in real time. In one embodiment, the element Outcome Tracking includes the parameters progression free survival, overall survival, performance status/quality of life metrics, incidence/severity of toxicity, (e.g., the degree to which a substance or drug can damage an individual), death, and drug utilization (e.g., delivered dose intensity, dose interval and duration of therapy) Other types of outcomes are also contemplated.
- the element ECOG performance status/quality of life metrics refers to a method by which the quality of life of the patient over time can be tracked. It is part of the demographic parameter disease specific clinical molecular phenotype, i.e., the stage of a patient's health at the start of therapy, and is within Sorting. For example, a comparison of ECOG at start of therapy (e.g., ECOG of 3), with ECOG after therapy (e.g., ECOG of 2) reflects the effect of the therapy.
- start of therapy e.g., ECOG of 3
- ECOG after therapy e.g., ECOG of 2
- exemplary parameters of the element Toxicity to Therapy are incidence and severity.
- COTA enables at risk financial contracting between payers and providers so the parties can reduce variability, waste and inefficiency but yet deliver on the intended outcome.
- the COTA module 220 can also transmit communications, such as alerts 330, to medical professionals (e.g., physicians) (or, in another embodiment, to a patient's insurance company or any other entity) in real-time at key points, such as, e.g., at diagnosis, at progression, at dose change/drug change/toxicity, and/or trending towards variance from desired outcome.
- the COTA module 220 provides alerts to medical professionals that identify a specific patient for which the medical professional is searching.
- the COTA module 220 may provide an alert in real time to a pharmaceutical company that is looking for specific patients to administer a specific (e.g., new) drug or drug candidate.
- the alert may identify a specific patient that is a good candidate for the specific drug.
- Fig. 4A is a block diagram illustrating sorting data associated with colon cancer patients in accordance with one embodiment. Although described with respect to cancer, e.g., colon cancer, the description and figure can apply to any type of cancer or, in another embodiment, any type of disease for which there is data associated with patients. [0078] Data 410 is gathered for all cancers (or, in another embodiment, for more than one type of cancer, or, in other embodiments, for all cardiovascular diseases, pulmonary diseases, gastrointestinal diseases, neurological diseases, etc), and this data 410 is narrowed to a subset 420 relating to, e.g., colon cancer.
- the subset 420 of data relating to colon cancer is then analyzed and sorted by the COTA module 220 to produce a sorted colon cancer data set 430.
- the sorted colon cancer data set 430 can include one or more groupings, where each grouping includes data associated with patients having the same type of specific colon cancer.
- the COTA module 220 enables the sorting of cancers to the highest level of fidelity.
- EMRs electronic medical records
- EMRs electronic medical records
- most of the information in EMRs is not relevant to the information for which the medical professional is searching.
- the COTA module 220 is targeted, as the module 220 enables a user to locate specific data associated with particular patients. Accordingly, the COTA module 220 can sort the data to locate specific, specialized information.
- the data that the COTA module 220 receives is typically via a web page, and is discrete (e.g., typically provided by a user selecting one or more choices in a drop down menu or via one or more check boxes).
- the COTA module classifies, sorts, and facilitates the grouping of types of patients based on these variables results in the designation of a unique COTA nodal address (CNA), which embodies those classification variables.
- CNA COTA nodal address
- data is ingested into the system via a human user or a technical process, e.g., an API, a layer (meaning a part of the application which performs a particular function) in the application looks at, and assesses, the information, e.g., whether it is correct, whether it is corrupt, what information is there, what information is missing//holes in the information, how it is formatted, spelling, etc., corrects any problems with the information it detects to date, and assigns a CNA to that set of information.
- a technical process e.g., an API
- a layer meaning a part of the application which performs a particular function
- the information e.g., whether it is correct, whether it is corrupt, what information is there, what information
- the CNA is an address to classify like data.
- the COTA module identifies the relationship between different characteristics in a grouping, which allows COTA to classify information on any patient in the grouping.
- the set of information sitting in the database is preassigned a CNA.
- the COTA module takes a large amount of information that encompasses many different attributes, allows the user to identify certain of the attributes as a set of
- the nodal address is a number that enables a user to specifically compare like patients to like patients. This specificity allows for minimizing biological variability of outcome and as a consequence provides greater precision regarding the effect of therapeutic agents on outcome.
- a user wants to validate personal health information (PHI) from a patient, make sure it is correct in every way, and then assign the appropriate CNA.
- PHI personal health information
- PHI refers to any information in a medical record or designated record set that can be used to identify an individual patient and that was created, used, or disclosed in the course of providing a health care service such as diagnosis or treatment.
- Examples of personal identifiers in PHI include, without limitation, name, all geographical subdivisions smaller than a state, including street address, city, county, precinct, zip code; all elements of dates (except year) for dates directly related to an individual, including birth date, admission date, discharge date, date of death, and all ages over 89 and all elements of date (including year) indicative of such age; phone numbers; fax numbers; electronic mail addresses; social security numbers, medical record numbers; health plan beneficiary numbers; account numbers; certificate/license numbers; vehicle identifiers and serial numbers, including license plate numbers; device identifiers and serial numbers; web Universal Resource Locators (URLs); Internet Protocol (IP) address numbers; biometric identifiers, including finger and voice prints; full face photographic images and any comparable images; and any other unique identifying number, characteristic, or code (but not the unique code assigned by the investigator to code the data).
- name all geographical subdivisions smaller than a state, including street address, city, county, precinct, zip code
- This PHI is input for patient A into a browser.
- the PHI gets sent to a classification layer and a CNA is assigned, the CNA defining attributes of patient A's record, and then into the database, i.e., the set of patient attributes, which falls under this type of CNA, is joined to the CNA.
- the database will return all of patient A's information and the CNA assigned. Accordingly, the user immediately understands how this patient's symptoms/attributes should be handled, i.e., the user gets a snapshot of how that type of patient relates to other patients whose information is in the database.
- Fig. 4B is a flow diagram of COTA classifying and sorting as described above through specific node creation in accordance with one embodiment
- an expert selects the variables sex or gender 440 (variable A), race 445 (variable B), . . ., and KRAS 450 (variable G).
- K-Ras is a protein that in humans is encoded by the KRAS gene.
- the protein product of the normal KRAS gene performs an essential function in normal tissue signaling, and the mutation of a KRAS gene is an important step in the development of many cancers.
- the COTA module 220 analyzes the classified and sorted data 430 with respect to these variables (e.g., variables 440, 445, 450) to generate a unique COTA node 455.
- the COTA module 220 may apply these nodes on the classified and sorted data to provide more clinically relevant results.
- the nodes are created as a set of preselected variables which are applied to further filter the classified and sorted data.
- the nodes are represented as nodal addresses indicating the preselected variables.
- the variables may include, e.g., diagnoses, demographics, outcomes, phenotypes, etc.
- a phenotype is the composite of a person's observable characteristics or traits, such as its morphology, development, biochemical or physiological properties, phenology, behavior, and products of behavior. Phenotypes result from the expression of a person' s genes as well as the influence of environmental factors and the interactions between the two.
- the variables of a node are selected by experts in the pertinent field in order to partition the data into clinically relevant results.
- the COTA node 455 is represented as a nodal address within the COTA module 220.
- the nodal address is represented as a list of the variables selected (as a function of a letter representing the variable and a number representing the selection within the variable).
- the node 455 includes Al-2 (A represents the sex or gender variable, and 1-2 represents Female and Male patients) shown with a block around both Female and Male variables of Sex variable A.
- the node 455 also includes Bl-4 because the node 455 includes the Race variable with all of the sub- variables selected (shown with a box around all of the Race variables).
- the node 455 also includes Gl, as with respect to the KRAS variable, only Mut-i- is selected (boxed). Thus, node 455 has a node address of Al-2, Bl-4..., Gl . [0085] In another embodiment, the node address is represented as a plurality of strings of digits separated by periods, where each string of digits indicates one or more variables (e.g., disease, phenotype, therapy type, progression/track, sex, etc.).
- variables e.g., disease, phenotype, therapy type, progression/track, sex, etc.
- a first string of digits may represent a particular disease
- a second string of digits may represent a type of the disease
- a third string of digits may indicate a subtype of the disease
- a fourth string of digits may indicate a phenotype.
- the first string of digits may be 01 indicating cancer
- the second string of digits may be 02 indicating breast oncology
- a third string of digits may be 01 indicating breast cancer
- a fourth string of digits may be 1201 representing particular characteristics of a phenotype such that the nodal address is 01.02.01.1201.
- the nodal address may include any number of strings of digits and is not limited to four strings.
- the string of digits representing the phenotype may be provided by representing characteristics of the phenotype as a directed graph.
- Fig. 4C illustratively depicts a directed graph 460 showing characteristics of a phenotype to provide a string of digits representing the phenotype in accordance with one embodiment.
- the directed graph 460 includes nodes representing phenotypes and edges representing a relationship between nodes. The graph is traced starting from root "start" node to nodes for a selected phenotype. Each edge is associated with a number.
- the string of digits representing the phenotype for the node address is provided as a combination of the numbers.
- the string of digits for selected phenotype characteristics of male and white would be represented as 11.
- Other types of combinations may also be employed.
- representing characteristics of the phenotype as a directed graph allows for the addition of other nodes without changing the entire structure.
- the screen' s appearance is a result of the CNA, and its appearance can be changed however it is desired to present the information.
- Node 455 provides the COTA module 220 with the ability to match resources and alerts specific to each phenotype where relevant.
- Resources can be information, content, link to live support, etc.
- Each patient is categorized into one or more nodal addresses.
- One or more nodes may also be associated with each disease.
- resources get "tagged" with appropriate, relevant nodes.
- nodes are fungible over time to stay current with scientific / medical advances.
- Each nodal address may be associated with one or more bundles of
- Each bundle may also be associated with one or more nodes.
- the services included in each bundle may be determined by one or more medical professionals, a hospital, a group, an insurance company, etc. to optimize patient care and/or cost.
- a bundle may indicate a number of imaging scans, a drug or choice of drugs, a schedule of when to administer the drugs, an operation or procedure, a number and frequency of follow up visits, etc.
- the bundling of patient care services may be particularly useful for risk contracting.
- each bundle corresponding to a nodal address associated with a particular disease
- the cost may be determined or negotiated based on historical data associated with that particular disease or nodal address.
- the bundling of services provides cost certainty to an insurance company and/or hospital for a particular disease. This also reduces the cost of processing and maintaining records. Additionally, medical professionals will know ahead of time the predetermined course of treatment, which provides incentives to physicians to obtain better outcomes at lower costs.
- ICD-10 International Statistical Classification of Diseases and Related Health Problems 10th Revision
- WHO World Health Organization
- ICD-10 International Classification of Diseases, 10th Revision
- Fig. 5A is a flowchart illustrating steps performed by the COTA module 220 in accordance with one embodiment.
- the COTA module 220 collects data records.
- the data records each include data associated with a disease (e.g., cancer).
- the data records may include patent data for patients who have or who previously had the disease.
- the data records may include diagnoses, demographics, outcomes, costs, or other pertinent information.
- the data records may be collected from an electronic database (e.g., an electronic medical record), provided by a user (e.g., medical professional, expert, specialist, etc.), or from any other source.
- the COTA module 220 stores the data records in database 240.
- the COTA module 220 receives one or more parameters to sort the data records.
- the one or more parameters may be received from the user computer 210 as user selected input.
- the one or more parameters may include, e.g., diagnoses, demographics, outcomes, costs, or any other parameter.
- the COTA module 220 sorts the data records based on the one or more parameters.
- the sorting identifies patients satisfying the one or more parameters. Patients are sorted to the highest level of clinical and/or molecular fidelity based on the latest scientific and/or medial guidelines accept in the pertinent field. In one embodiment, the sorting is performed in real time.
- the classified and sorted data records are filtered according to a nodal address.
- the nodal address represents variables preselected by users to provide a set of clinically relevant patients.
- the variables of a nodal address are selected by experts in the field.
- the nodal address may be represented as a plurality of strings of digits each separated by a period.
- the each string of digits may represent one or more variables (e.g., a disease, type of disease, subtype of disease, phenotypes, or any other relevant variable). Other representations of the nodal address are also contemplated.
- the data records for the clinically relevant patients are analyzed. Analyzing the data records may include tracking (e.g., in real time) clinical outcomes of patients associated with the disease.
- the outcomes may include, for example, delivered dose intensity, therapeutic agents received, dose, dose interval, and dose duration, incidence and severity of toxicity, cost, progression free survival (PFS), overall survival (OS), response rates, etc.
- the COTA module 220 may compare the tracked outcomes between patients.
- the COTA module 220 may also determine, based on the tracking, whether a specific doctor associated with a tracked patient is treating the patient in accordance with treatment techniques of other doctors treating other (similar) patients. In one embodiment, the COTA module 220 determines this based on the outcomes of many patients.
- analyzing the data records may include updating (e.g., in real time) at least some of the data records based on the tracked outcomes. For example, the COTA module 220 may determine that patient ABC had colon cancer, was prescribed and has taken medication XYZ for two years, and is now in remission for the past 3 years. If the COTA module 220 determines this information from the tracking of patient ABC, the module 220 can update the data record associated with patient ABC with this information.
- analyzing the data records includes performing an analysis to determine patient survival rate, such as, e.g., by creating a Kaplan Meier curve.
- a Kaplan Meier curve is a curve that shows five year survival rate that can be developed, e.g., for a single doctor (or medical professional) or for a group of doctors (or medical professionals).
- a Kaplan Meier curve can be created for overall survival and/or progression free survival. Other types of analyses are also contemplated.
- the COTA module 220 may also include an analysis tool to the user computer 210 and/or user computer 230.
- This analysis tool may be a user interface that is accessible via a web page, a tab on an existing web page, a software application, an app, etc.
- the user interfaces as depicted in the figures herein are exemplary. This analysis tool may enable a user to compare, analyze, or further sort the data records.
- the COTA module 220 provides a communication based on the analysis.
- the communication may be in the form of an alert to a user.
- the COTA module 220 may communicate the classified and sorted data records and/or the updated data records to the user computer 210 and/or user computer 230.
- the COTA module 220 communicates a table, chart, list, link, etc. that enables the user to access the sorted or updated data records.
- the COTA module 220 may transmit advertisements with (e.g., related to) the data records to the user computer 210 and/or user computer 230.
- the COTA module 220 may identify a specific patient as a candidate for a specific treatment or drug.
- the COTA module 220 may transmit the communication to the user computer 210, user computer 230, or any other entity (e.g., via network 215).
- the COTA module 220 can be used by and benefit many people, professionals, and/or companies.
- the highly specialized pipeline of pharmaceutical companies likely requires a new business model for many aspects (e.g., development including Phase 4 trials / post-marketing surveillance, marketing, sales, pricing, and contracting).
- the professionals at the pharmaceutical companies can use the COTA module 220 to facilitate this new business model.
- the COTA module 220 can match the right patient to the right drug.
- the COTA module 220 can enable precise patient identification via its sorting and nodal addressing abilities.
- the COTA module 220 provides a matching function that enables a user (e.g., a pharmaceutical company) to locate (e.g., in real time) one or more patients that are or would be good candidates for a specific drug that the pharmaceutical company has released or is developing.
- a user e.g., a pharmaceutical company
- the COTA module 220 may benefit health plans. As indicated above, cancer care will likely become more complex, and it will likely not be efficient for health plans to continue with direct management. In one embodiment, health plans outsource their cancer care to the COTA module 220 (similar to what health plans previously did with pharmacy benefits). This may reduce their costs, such as by reducing total cost of care and providing cost offsets for them, such as by replacing pathways, decreasing expensive prior authorization infrastructure, decreasing other personnel who "manage cancer". Additionally, provisions in the U. S. Affordable Care Act state that 85% of premiums must go to clinical care related activities versus administrative costs. In one embodiment, the COTA module 220 provides an analytic interface with connections to claims data to support health plans in managing their oncologists.
- the COTA module 220 can benefit organizations engaged in diagnostic methods or tools. Organizations engaged in diagnostic methods or tools, such as those involved in next generation genetic sequencing, will likely need an efficient education, marketing and sales/distribution channel. Because the COTA module 220 is able to precisely sort and identify patients and send time based alerts to physicians (or other medical professionals), its use may benefit such organizations.
- Fig. 5B is a flow chart illustrating steps for enabling a patient diagnosed with a condition to optimize his/her treatment options, in accordance with an embodiment.
- the steps of Fig. 5B may be performed by the COTA module 220 executing on server computer 205.
- the COTA module 220 executing on server computer 205 may interact with a user (e.g., a patient) via the COTA module 220 executing on user computer 210 and/or may interact with a user (e.g., a medical professional) via the COTA module 220 executing on user computer 230 over network 215.
- the COTA module 220 may include multiple instances of COTA module 220 for execution on server computer 205, user computer 210, and user computer 230.
- the COTA module 220 executing on server computer 205 receives a communication from user computer 210 of the patient.
- the communication may include an indication that the patient is seeking treatment options, a medical professional, or any other indication.
- the COTA module 220 executing on server computer 205 is communicatively linked to database 240 comprising personal health information for a population of patients, which may or may not include health information of the patient.
- the COTA module 220 executing on server computer 205 is configured to analyze the personal health information stored in database 240. This may be performed as a pre-processing step, prior to receiving the communication from the patient.
- the COTA module 220 executing on server computer 205 may analyze the personal health information as described herein by sorting and classifying the personal health information and assigning a plurality of nodal addresses to the each patient in the population of patients, measuring clinical outcomes for each nodal address, and measuring behavioral variance for each medical care provider assigned to each nodal address.
- the health information may be received from the COTA module 220 executing on user computer 210.
- the health information of the patient may include the condition with which that the patient is diagnosed.
- the condition is selected with specificity by the patient via the COTA module 220 executing on user computer 210 from lists and sublists of conditions available in the database 240 of computer server 205.
- the COTA module 220 executing on server computer 205 determines a list of tests for further classifying the condition based on the received health information of the patient.
- step 560 the list of tests needed by the COTA module 220 executing on server computer 205 for further classifying the condition is sent to the COTA module 220 executing on user computer 210.
- results of the tests are received from the COTA module 220 executing on user computer 210.
- the results of the tests may be sent from the patient after completing initial treatment and with permission from the patient to a medical professional to provide the results of the tests to the COTA module 220 executing on server computer 205.
- a nodal address is assigned to the patient based on the results of the tests.
- the assigned nodal address may be assigned from the plurality of nodal addresses generated during the pre-processing step by the COTA module 220 executing on server computer 205 for the population of patients.
- the assigned nodal address includes the set of preselected variables effective to partition the sorted and classified personal health information into a clinically relevant set of health information.
- the assigned nodal address is associated with one or more bundles of predetermined patient care services (e.g., treatment plans) for treatment of the condition.
- the predetermined patient care services may be determined by one or more of a medical professional, a hospital, a medical group, or an insurance company.
- the bundles of predetermined patient care services may provide a predetermined course of treatment.
- the bundles of predetermined patient care services may provide cost certainty for the condition.
- the COTA module 220 executing on server computer 205 transmits the assigned nodal address and a geographically organized list of medical professionals treating patients within the assigned nodal address to the COTA module 220 executing on user computer 210.
- the geographically organized list of medical professionals may be visually classified by clinical outcome.
- the geographically organized list of medical professionals may be visually classified by clinical outcome according to color. For example, the geographically organized list of medical professionals may be visually classified such that green signifies a better than average clinical outcome, yellow signifies average clinical outcome, and red indicates poorer than average clinical outcome.
- a selection of a candidate medical professional is received.
- the selected candidate medical professional may be selected by the patient to meet one or more of geographical limitations, clinical outcome criteria, and cost criteria set by the patient.
- each medical professional is further classified within the group of candidate medical professionals based on cost of care. For example, each medical professional may be further classified as being more, less, or substantially the same as the selected candidate medical professional.
- user computer 210 of the patient is communicatively linked to user computer 230 of a medical professional (e.g., at the office of the selected candidate medical professional) to facilitate scheduling of an appointment with the selected candidate medical professional.
- the COTA module 220 executing on server computer 205 transmits the personal health information of the patient to the COTA module 220 executing on user computer 230 of the medical professional.
- the steps of Fig. 5B enable a patient diagnosed with a condition to optimize treatment options based on geographical limitations, clinical outcome, and cost criteria of the patient.
- Fig. 6 illustrates a flow diagram 600 of alerts provided by the COTA module 220 in accordance with an embodiment.
- physicians or other medical professionals are alerted based on their preferences. These preferences can be set by the medical professional/physician and can include, for example, triggers 610 for the alerts and/or the technique used to provide the alert.
- a trigger for an alert can include, for example, at new patient diagnosis 615, an update to a diagnosis, real-time scheduled event, changes to group membership (e.g., a new gene identified which might change grouping, and/or someone leaving the group), toxicity and/or dose intensity change 620, at disease progression 625, administration of a particular drug, trending towards variance from desired outcome 630, and/or prospective time or cycle dependent alerts 635 (e.g., side effect alerts and/or diagnostic test reminders).
- the alert may include a text message 640 or an email 645 sent to the user computer 210.
- alerts are also contemplated, such as, e.g., a telephone call to the user computer 210, an update on a web page, a social media update, a message sent using, e.g., Twitter®, Facebook®, or other social media site, adding content to a software library or web page, and/or any other message or communication sent to or accessed by the user computer 210.
- a trigger can be any action that results in the COTA module 220 performing any other action.
- Fig. 7 is a graphical representation illustrating a mobile device 705 (e.g., user computer 210) organizing alerts received by the device 705 in accordance with one embodiment.
- the COTA alerts received are listed by a title or subject, such as New Colon CA 710, New Renal Cell CA 715, Dose Adjustment 720, Drug
- CHOP is an abbreviated name of a combination of drugs used in chemotherapy, which includes cyclophosphamide
- the COTA module 220 can provide specific disease data sets (e.g., on demand and in real time) including, for instance, incidence of disease (e.g., by a COTA sort), progression free survival by progression status, and/or overall survival.
- the COTA module 220 can provide a drug utilization data set, such as data associated with a full or partial therapy, toxicity, and/or a change in therapy.
- Fig. 8 shows a graphical representation 800 of incidence of disease by cancer subtype that can be provided by the COTA module 220 in accordance with one embodiment.
- the COTA graph 800 is for lymphoma from years 2010 to 2013.
- a user can utilize a graph search input section 810 to narrow the information that is graphed.
- the graph search input section 810 can include, for example, a selection of what to report for (e.g., minimal diagnosis, complete diagnosis, and/or audited patient, diagnosis type, cancer site / subtype, ICD9 (International Classification of Diseases, Ninth Revision) code, Co-Morbidity, Disease Progression, Gender, Age, Date Range, Race, Diabetes, History of Tobacco Use, History of Prior Chemotherapy or Radiation, etc.
- ICD9 International Classification of Diseases, Ninth Revision
- Fig. 9 shows a graphical representation 900 of a sort based on variables input into the COTA module 220 that can be provided by the COTA module 220 in accordance with one embodiment.
- the graphical representation 900 shows a COTA graph for Hodgkin' s Lymphoma from years 2010 - 2013 split out by male vs. female.
- the graphical representation 900 shows a COTA graph for Hodgkin' s Lymphoma from years 2010 - 2013 split out by male vs. female.
- the graphical representation 900 shows a COTA graph for Hodgkin' s Lymphoma from years 2010 - 2013 split out by male vs. female.
- the graphical representation 900 shows a COTA graph for Hodgkin' s Lymphoma from years 2010 - 2013 split out by male vs. female.
- the graphical representation 900 shows a COTA graph for Hodgkin' s Lymphoma from years 2010 - 2013 split out by male vs
- representation 900 shows statistics 910 of the different patients who had this disease that were graphed in representation 900.
- Fig. 10 shows an exemplary listing of a plurality of variables 1005 pertinent to a particular disease (here, variables shown are for lymphoma) in accordance with one embodiment.
- Fig. 11 shows a graphical representation 1100 including real-time Kaplan Meier curves with confidence intervals for pancreatic cancers that can be provided by the COTA module 220 in accordance with one embodiment.
- a Kaplan Meier curve is a curve that shows five year survival rate that can be developed, e.g., for a single doctor (or medical professional) or for a group of doctors (or medical professionals).
- a Kaplan Meier curve can be created for overall survival and/or progression free survival. The user indicates variables for his graph search in graph search input section 1110.
- Fig. 12 is a graphical representation 1200 showing Kaplan Meier curves for disease progression that can be provided by the COTA module 220 in accordance with one embodiment.
- Line 1205 is for all pancreatic cancers, and bold line 1210 is for those with first progression.
- Fig. 13 is a graphical representation 1300 of real time benchmarking of outcomes between two parties that can be provided by the COTA module 220 in accordance with one embodiment.
- the graph 1300 includes curve 1305 for outcomes of Dr. John Doe, a physician who treats pancreatic cancer, and a curve 1310 for outcomes of the rest of the doctors who treat pancreatic cancer.
- Fig. 13 also includes a meter 1320 measuring whether Dr. John Doe's outcomes are tracking positively or negatively.
- Fig. 14 is a graphical representation of a cost report 1400 associated with (e.g., provided by) the COTA module 220 in accordance with one embodiment.
- the screen' s appearance is a result of the CNAs and its appearance can be changed however it is desired to present the information.
- the cost report 1400 may be associated with the cost tab 1220 of Fig. 12.
- the cost report 1400 can be used, for example, in estimating cost(s) of treatment, capturing knowledge, and/or transforming the knowledge into specific implementations.
- the COTA module 220 tracks costs of various treatments, physicians, hospitals, etc. in real time. As shown in Fig. 14, the cost report 1400 illustrates a comparison between physician and average cost per revenue.
- Cost report 1400 may also include other comparisons, such as, e.g., hospital contribution margin in dollars and percent, hospital average revenue and cost (e.g., average revenue per patient, average cost per patient), physician average cost per case (e.g., average cost per case for each physician, weight peer average), physician average cost per revenue (e.g., average cost of imaging, lab work, evaluation and management, pharmaceuticals, medical supplies, and other expenses for each physician), etc.
- hospital average revenue and cost e.g., average revenue per patient, average cost per patient
- physician average cost per case e.g., average cost per case for each physician, weight peer average
- physician average cost per revenue e.g., average cost of imaging, lab work, evaluation and management, pharmaceuticals, medical supplies, and other expenses for each physician
- Fig. 15A and 15B are graphical representations of a treatment interface 1500 associated with (e.g., provided by) the COTA module 220 for facilitating the connection between outcomes and treatments, in accordance with one embodiment.
- the treatment interface 1500 may include a list the different types of treatment administered to (or declined by) a patient with breast cancer, such as, e.g., surgery, antineoplastic drugs, cellular therapy, radiation therapy, etc.
- Treatment may be arranged according to a disease progression. For example, drugs in oncology are typically given in cycles, and, in any one cycle, any number of drugs can be given.
- a user can select a progression (e.g., represented as progression 0 to progression 4), with progression 0 being after first diagnosis, cycle, and can select drugs in or from multiple categories.
- a treatment interface 1510 may include treatment regimens for one or more therapies, graphically represented on treatment interface 1510 as tabs 1515.
- Treatment interface 1510 may include fields to indicate a start and end data for the regimen, dose intensity, description of treatment, specific brands of drugs, etc.
- Treatment regimens may be graphically summarized or represented as a listing of treatments in table 1520.
- Table 1520 may include action icons 1505 for each treatment.
- the action icons 1505 may facilitate actions, such as, e.g., editing, closing, viewing components, etc.
- the action icons 1505 may be shortcuts to perform complex tasks (e.g., requiring multiple clicks or selections) with a single selection. For example, an icon on the diagnosis line can bring the user to the diagnosis screen.
- Fig. 16 is a graphical representation of an outcome screen 1600 for facilitating outcome tracking in accordance with one embodiment.
- Outcome screen 1600 may facilitate outcome tracking from, for example, diagnosis (i.e., progression zero), first progression, second progression through fourth progression, with each progression considered a different disease.
- the outcome screen tab can include (e.g., in one or more drop down menus or other fields) a diagnosis date, a treatment start and end date, a response to treatment (e.g., complete, partial, stable) and date of response, input fields for notes on the response (e.g., the partial field, CR-RA-Pet Negative field, the CR field, etc.), and a track end data, which may include fields for last contact and death.
- the outcome screen 1600 may also include other fields, such as, e.g., toxicity of a drug treatment, an input area enabling the input of what happened (e.g., discontinued, continued, no change, drug dosage change, and how many times), number of delays, number changes in drug, and/or number reduced.
- a user of the COTA module 220 can flag a patient.
- Fig. 17 is a graphical representation of a treatment details report screen 1700 illustrating a comparison between cost and outcome in accordance with one embodiment.
- the treatment details report screen 1700 correlates cost of care to clinical outcome to optimize value of care.
- Cost and financial data may be collected and analyzed by hospital, by doctor, etc. over a given time period (e.g., 5 years).
- the cost and financial data may be represented in one or more ranges of cost.
- the ranges of cost include range 1705 for cost greater than $25,000, range 1710 for cost from $10,000 to $25,000, and range 1715 for cost less than $10,000.
- the COTA module 220 may provide cost data for different treatments for a given time period based on different clinical sorts.
- Fig. 18 is a graphical representation of an analysis screen 1800 provided by the COTA module 220 illustrating a comparison between toxicity and cost in accordance with one embodiment.
- the screen' s appearance is a result of the CNAs and its appearance can be changed however it is desired to present the information.
- the analysis screen 1800 correlates incidence and severity of toxicity to cost of care and outcomes of care.
- the toxicity may be represented numerically (e.g., in ranges), by standards (e.g., grades), etc.
- toxicity is represented as toxicity grades 1-4 based on the Common Terminology Criteria for Adverse Events (CTCAE) classification.
- CTCAE Common Terminology Criteria for Adverse Events
- the grade of toxicity is graphically compared with cost.
- the analysis screen 1800 may be used to optimize value and efficacy of care, where value is efficacy/cost. In one embodiment, the COTA module 220 attempts to obtain high efficacy and low cost.
- Fig. 19 is a graphical representation of an analysis screen 1900 provided by the COTA module 220 illustrating a comparison between therapy and quality of life in accordance with one embodiment.
- the therapy may be represented by treatment drugs in analysis screen 1900.
- other forms of therapy are also contemplated, such as, e.g., surgery, procedures, etc.
- the therapy includes an incidence, severity, and toxicity of therapy.
- Quality of life may be measured based on the average ECOG (Eastern Cooperative Oncology Group) scale, ranging from Grade 0 (i.e., fully active) to Grade 5 (i.e., dead). Quality of life may also be measured using any suitable metric.
- Analysis screen 1900 may facilitate assessment of how a patient' s disease is progressing, how the disease affects the daily living abilities of the patient, and appropriate treatments and prognoses.
- Fig. 20 is a flow diagram 2000 illustrating the alert system provided to a medical professional in accordance with one embodiment.
- the screen' s appearance is a result of the CNAs and its appearance can be changed however it is desired to present the information.
- the information in the alert is helping the user to make a decision in the future.
- the information in the alert is providing a set of attributes that happened in the past time period. In one embodiment, it is both proactively influencing decisions of the user and reactively providing a digest report of how the medical
- alerts for different users, each of which can influence decisions that the user makes.
- the alert may be employed for real time course correction to drive best value, such as, e.g., where an administered therapy deviates from a desired outcome.
- definitions are triggered based on clinical data.
- the definitions may be triggered using any criteria, such as, e.g., new disease diagnosis, disease progression, patient response, change in patient characteristics, dose change/drug toxicity change, trend towards variance from a desire outcome, etc.
- the criteria may be adjusted based on the disease and its parameters.
- alerts 2010-A, 2010-B, 2010-C are transmitted. It should be understood that alerts 2010 may include any number of alerts.
- the alerts 2010 may include content or a link to content.
- the alerts 2010 may be transmitted to the responsible physician, other medical professionals, hospital,
- Content 2015-A, 2015-B, 2015-C (collectively referred to as content 2015) is displayed, e.g., using user computer 210 to provide the alert.
- the content 2015 may include the patient data associated with the alert 2010, a comparison, or any other relevant content.
- the comparison may be, e.g., between physicians, between one physician' s patients and the whole patient population, between one physician and all physicians at a particular location, etc.
- the comparison may be based on a trending analysis to show where treatment is trending and if it is going off course (i.e., results are not as good as the standard).
- the comparison may be graphically displayed as one or more curves on a graph.
- the COTA module 220 is utilized with cloud-based computing.
- the COTA module 220 can also enable or utilize connectivity to hospital records.
- the content 2015 may include feedback support to the medical professional having traffic light feedback indicators (not shown) on a display.
- traffic light feedback indicators (not shown) on a display.
- blue may mean very good performance (i.e., better than standard)
- green may mean standard performance
- yellow may mean sufficient performance but may need to pay attention
- red may mean the user may need to pay attention to something regarding the medical professional' s approach to this disease.
- Other implementations of feedback indicators may also be employed.
- Figs. 21-24 show graphical representations for different diagnosis types in accordance with one or more embodiments.
- Fig. 21 shows a diagnosis screen 2100 for gastrointestinal oncology (e.g., colon cancer).
- Fig. 22 shows a diagnosis screen 2200 for breast oncology (e.g., breast cancer).
- Fig. 23 shows a diagnosis screen 2300 for thoracic oncology (e.g., lung cancer).
- Diagnosis screens 2100, 2200, 2300 include a number of different parameters, such as tests or aspects of the disease. The parameters may be represented as simple indicators, numerically based parameters, standards based parameters, etc.
- Fig. 24 shows a graphical representation of a reporting screen 2400 illustrating the COTA module 220' s data generation and sorting for breast oncology.
- Reporting screen 2400 shows breast cancer from year 2008 to year 2013 by histology, i.e., with invasive ductal carcinoma, in accordance with one embodiment.
- the reporting screen 2400 permits selection of breast cancer patients based on stage, age, progression, or any other parameter in real time.
- reporting screen 2400 allows categorization in a clinically relevant way.
- Fig. 25 shows a graphical representation of a reporting screen 2500 illustrating the COTA module 220' s data generation and sorting for breast oncology.
- Reporting screen 2500 shows all grade 2 breast cancer from year 2008 to year 2013 tumor by stage, in accordance with one embodiment.
- Fig. 26 shows a graphical representation of a reporting screen 2600 illustrating the COTA module 220' s data generation and sorting for breast cancer.
- Reporting screen 2600 shows all stage IIB breast cancers from year 2008 to 2013, in accordance with one embodiment.
- Graph 2605 on reporting screen 2600 shows all stage IIB breast cancers by progesterone receptor status.
- Fig. 27 shows a graphical representation of an analysis screen 2700 illustrating overall survival outcomes for breast cancer patients in accordance with one embodiment.
- Fig. 28 shows a graphical representation 2800 illustrating survival outcomes for breast cancer as a comparison between Dr. John Doe (bold line) and the aggregate (non-bold line) parties, in accordance with one embodiment.
- the "node” described above represents every possible permutation of the variables shown in one or more of the graphical representations (e.g., in one or more of Figs. 21-27).
- client device 2905 may include one or more processing units (also referred to herein as CPUs) 2922, which interface with at least one computer bus 2925.
- Client device 2905 may be, for example, user computer 210.
- a memory 2930 can be persistent storage and interfaces with the computer bus 2925.
- the memory 2930 includes RAM 2932 and ROM 2934.
- ROM 2934 includes a BIOS 2940.
- Memory 2930 interfaces with computer bus 2925 so as to provide information stored in memory 2930 to CPU 2922 during execution of software programs such as an operating system 2941, application programs 2942, device drivers, and software modules 2943, 2945 that comprise program code, and/or computer-executable process steps, incorporating functionality described herein, e.g., one or more of process flows described herein.
- CPU 2922 first loads computer-executable process steps from storage, e.g., memory 2932, data storage medium / media 2944, removable media drive, and/or other storage device.
- CPU 2922 can then execute the stored process steps in order to execute the loaded computer-executable process steps.
- Stored data e.g., data stored by a storage device, can be accessed by CPU 2922 during the execution of computer-executable process steps.
- Persistent storage medium/media 2944 is a computer readable storage medium(s) that can be used to store software and data, e.g., an operating system and one or more application programs. Persistent storage medium/media 2944 can also be used to store device drivers, such as one or more of a digital camera driver, monitor driver, printer driver, scanner driver, or other device drivers, web pages, content files, playlists and other files. Persistent storage medium / media 2206 can further include program modules and data files used to implement one or more embodiments of the present disclosure.
- a computer readable medium stores computer data, which data can include computer program code that is executable by a computer, in machine readable form.
- a computer readable medium may comprise computer readable storage media, for tangible or fixed storage of data, or communication media for transient interpretation of code-containing signals.
- Computer readable storage media refers to physical or tangible storage (as opposed to signals) and includes without limitation volatile and non- volatile, removable and non-removable media implemented in any method or technology for the tangible storage of information such as computer-readable instructions, data structures, program modules or other data.
- Computer readable storage media includes, but is not limited to, RAM, ROM, EPROM, EEPROM, flash memory or other solid state memory technology, CD-ROM, DVD, or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other physical or material medium which can be used to tangibly store the desired information or data or instructions and which can be accessed by a computer or processor.
- Client device 2905 can also include one or more of a power supply 2926, network interface 2950, audio interface 2952, a display 2954 (e.g., a monitor or screen), keypad 2956, illuminator 2958, I/O interface 2960, a haptic interface 2962, a GPS 2964, a microphone 2966, a video camera, TV / radio tuner, audio/video capture card, sound card, analog audio input with A/D converter, modem, digital media input (HDMI, optical link), digital I/O ports (RS232, USB, FireWire, Thunderbolt), expansion slots (PCMCIA,
- a power supply 2926 e.g., network interface 2950, audio interface 2952, a display 2954 (e.g., a monitor or screen), keypad 2956, illuminator 2958, I/O interface 2960, a haptic interface 2962, a GPS 2964, a microphone 2966, a video camera, TV / radio tuner, audio/video capture card
- a module is a software, hardware, or firmware (or combinations thereof) system, process or functionality, or component thereof, that performs or facilitates the processes, features, and/or functions described herein (with or without human interaction or augmentation).
- a module can include sub-modules.
- Software components of a module may be stored on a computer readable medium. Modules may be integral to one or more servers, or be loaded and executed by one or more servers. One or more modules may be grouped into an engine or an application.
- Fig. 30 is a block diagram illustrating an internal architecture of an example of a computer, such as server computer 205, user computer 210, and/or user computer 230, in accordance with one or more embodiments of the present disclosure.
- a computer as referred to herein refers to any device with a processor capable of executing logic or coded instructions, and could be a server, personal computer, set top box, tablet, smart phone, pad computer or media device, to name a few such devices.
- internal architecture 3000 includes one or more processing units (also referred to herein as CPUs) 3012, which interface with at least one computer bus 3002.
- persistent storage medium/media 3006 is also interfacing with computer bus 3002
- memory 3004 e.g., random access memory (RAM), run-time transient memory, read only memory (ROM), etc.
- media disk drive interface 2308 as an interface for a drive that can read and/or write to media including removable media such as floppy, CD-ROM, DVD, etc. media
- display interface 3010 as interface for a monitor or other display device
- keyboard interface 3016 as interface for a keyboard
- pointing device interface 3018 as an interface for a mouse or other pointing device
- USB universal serial bus
- Memory 3004 interfaces with computer bus 3002 so as to provide information stored in memory 3004 to CPU 3012 during execution of software programs such as an operating system, application programs, device drivers, and software modules that comprise program code, and/or computer-executable process steps, incorporating functionality described herein, e.g., one or more of process flows described herein.
- CPU 3012 first loads computer-executable process steps from storage, e.g., memory 3004, storage medium/media 3006, removable media drive, and/or other storage device.
- CPU 3012 can then execute the stored process steps in order to execute the loaded computer-executable process steps.
- Stored data e.g., data stored by a storage device, can be accessed by CPU 3012 during the execution of computer-executable process steps.
- persistent storage medium/media 3006 is a computer readable storage medium(s) that can be used to store software and data, e.g., an operating system and one or more application programs. Persistent storage medium/media 3006 can also be used to store device drivers, such as one or more of a digital camera driver, monitor driver, printer driver, scanner driver, or other device drivers, web pages, content files, playlists and other files. Persistent storage medium/media 3006 can further include program modules and data files used to implement one or more embodiments of the present disclosure.
- Internal architecture 3000 of the computer can include (as stated above), a microphone, video camera, TV / radio tuner, audio/video capture card, sound card, analog audio input with A/D converter, modem, digital media input (HDMI, optical link), digital I/O ports (RS232, USB, FireWire, Thunderbolt), and/or expansion slots (PCMCIA, ExpressCard, PCI, PCIe).
- CNA-guided care has two faces, which together, through the triad of a health care provider, a payer, and the patient suffering from a disease, enables value based care delivery in the United States through the application of CNAs.
- the first face comprises interactions between a medical care provider, a computer containing a processor comprising a first COTA module, a first client device comprising a second COTA module that is communicatively linked to the first COTA via a network, and a payer. It enables a payer to transmit via the first client device comprising a second COTA module communicatively linked to the first COTA module of the processor, a communication over the network to the processor identifying a health care service under consideration for a patient whose health plan benefits cover the service; indicating that the service is for the purpose of diagnosing or treating a medical condition; and identifying variables selected by the payer.
- the first COTA module can transmit to the second COTA module information comprising (i) the clinical outcome data for each CNA, (ii) the adverse variance data for each medical provider at each CNA including both necessary care that is absent and unnecessary care contributing to the medical care provider's adverse variance for patients at each nodal address at key points in time during treatment; (iii) a cost report comprising cost data in real time for treating each patient in the patient population assigned to the CNA; and (iv) graphic analyses correlating one or more of (1) cost of care to clinical outcome; (2) incidence and severity of toxicity to cost of care and clinical outcome of care; and (3) therapy and quality of life.
- the payer when the payer can establish at key points in time, (a) that the medical service is an appropriate delivery or level of service, considering potential benefits and harms to the patient; (b) that the medical service is effective in improving health outcome by improving clinical outcomes and reducing total cost of care; that the service is cost-effective for the medical condition being treated and the clinical outcome, compared to alternative health interventions or no intervention; and that the service follows generally accepted medical practice, the payer can approve payment to the medical care provider for the medical service for the patient.
- the second face of CNA-guided healthcare in accordance with an embodiment of the present disclosure for a patient with breast cancer comprises interactions between the computer containing the processor comprising the first COTA module, a second client device comprising a third COTA module that is
- the first COTA module Upon exchanging a series of communications with the patient via the second client device comprising the third clinical outcome tracking and analysis module, the first COTA module does three things: it provides information to the patient so that the patient gets a complete medical evaluation of his/her condition (e.g., physical evaluation; laboratory evaluation; imaging, etc.) so that a CNA can be assigned; using the assigned CNA it shows the patient treatment options for the condition that optimize care and reduce risk of adverse variance; and it shows the patient doctors in his/her geographic area who follow CNA-Guided Care and have the best outcomes at an acceptable cost of care so that the patient can select a health care provider and a desired level of CNA-guided care, [00148] As depicted in Figure 32, from the payer's vantage point, the enabling tool can be effective to eliminate precertification for testing, diagnostics, and therapeutic choices; eliminate prior authorization; and eliminate the need for referrals.
- his/her condition e.g., physical evaluation; laboratory evaluation; imaging, etc.
- the enabling tool
- CNA- guided care does three things: first, it provides the patient with information sufficient for the patient to get a complete medical evaluation of his/her condition and for assigning a CNA to the patient; second, using the CNA, it shows the patient treatment options based on geography, clinical outcome, cost and other patient-set criteria, which enables the patient to select care optimized to avoid adverse variance; third it shows the patient health care providers in his/her area who follow CNA guided care that have the best outcomes at an acceptable cost of care.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Business, Economics & Management (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Business, Economics & Management (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Human Resources & Organizations (AREA)
- Data Mining & Analysis (AREA)
- Entrepreneurship & Innovation (AREA)
- Strategic Management (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Economics (AREA)
- Marketing (AREA)
- Operations Research (AREA)
- Quality & Reliability (AREA)
- Tourism & Hospitality (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/351,099 US9734291B2 (en) | 2013-10-08 | 2016-11-14 | CNA-guided care for improving clinical outcomes and decreasing total cost of care |
PCT/US2017/060778 WO2018089584A1 (en) | 2016-11-14 | 2017-11-09 | Cna-guided care for improving clinical outcomes and decreasing total cost of care |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3539034A1 true EP3539034A1 (en) | 2019-09-18 |
EP3539034A4 EP3539034A4 (en) | 2021-01-13 |
Family
ID=62110791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17869390.9A Pending EP3539034A4 (en) | 2016-11-14 | 2017-11-09 | Cna-guided care for improving clinical outcomes and decreasing total cost of care |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3539034A4 (en) |
JP (2) | JP7079790B2 (en) |
KR (1) | KR102579786B1 (en) |
CN (1) | CN110168659A (en) |
CA (1) | CA3042279A1 (en) |
IL (1) | IL266481B1 (en) |
WO (1) | WO2018089584A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101994691B1 (en) | 2016-07-14 | 2019-07-01 | 엘지전자 주식회사 | Robot Cleaner |
CN113569907A (en) * | 2021-06-11 | 2021-10-29 | 陆馨雨 | Disease treatment cost prediction method, system, medium and terminal |
KR102447046B1 (en) * | 2022-06-03 | 2022-09-26 | 주식회사 인투인월드 | Method, device and system for designing clinical trial protocol based on artificial intelligence |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7353238B1 (en) * | 1998-06-12 | 2008-04-01 | Outcome Sciences, Inc. | Apparatus and methods for determining and processing medical outcomes |
JP2001282922A (en) * | 2000-03-28 | 2001-10-12 | Toshiba Corp | Method and terminal for exchanging patient medical information |
US8200775B2 (en) * | 2005-02-01 | 2012-06-12 | Newsilike Media Group, Inc | Enhanced syndication |
US20050154614A1 (en) * | 2003-11-03 | 2005-07-14 | Swanson Ian S. | System and method for providing a national medical records database |
US8067451B2 (en) * | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
CA2702406C (en) * | 2007-10-12 | 2018-07-24 | Patientslikeme, Inc. | Processor-implemented method and system for facilitating a user-initiated clinical study to determine the efficacy of an intervention |
US20090216558A1 (en) * | 2008-02-27 | 2009-08-27 | Active Health Management Inc. | System and method for generating real-time health care alerts |
NZ627239A (en) * | 2008-03-26 | 2015-12-24 | Theranos Inc | Methods and systems for assessing clinical outcomes |
US20120130737A1 (en) * | 2009-09-17 | 2012-05-24 | Therapeuticsmd, Inc. | System and method for distrubutor reporting and analysis |
US20120166218A1 (en) * | 2010-12-27 | 2012-06-28 | Bruce Reiner | Method and system of real-time customizable medical search analytics |
US20120271612A1 (en) * | 2011-04-20 | 2012-10-25 | Barsoum Wael K | Predictive modeling |
US20130144790A1 (en) * | 2011-12-06 | 2013-06-06 | Walter Clements | Data Automation |
WO2013093692A2 (en) * | 2011-12-21 | 2013-06-27 | Koninklijke Philips Electronics N.V. | Method and system to predict physiologic and clinical status changes |
US20140006044A1 (en) * | 2012-06-27 | 2014-01-02 | Infosys Limited | System and method for preparing healthcare service bundles |
CA2926703C (en) * | 2013-10-08 | 2023-10-10 | COTA, Inc. | Clinical outcome tracking and analysis |
US20150161331A1 (en) * | 2013-12-04 | 2015-06-11 | Mark Oleynik | Computational medical treatment plan method and system with mass medical analysis |
US20160203270A1 (en) * | 2015-01-12 | 2016-07-14 | Edison Sabala | Comprehensive palliative and hospice care platform |
-
2017
- 2017-11-09 EP EP17869390.9A patent/EP3539034A4/en active Pending
- 2017-11-09 KR KR1020197017064A patent/KR102579786B1/en active IP Right Grant
- 2017-11-09 CA CA3042279A patent/CA3042279A1/en active Pending
- 2017-11-09 WO PCT/US2017/060778 patent/WO2018089584A1/en active Application Filing
- 2017-11-09 IL IL266481A patent/IL266481B1/en unknown
- 2017-11-09 CN CN201780083458.XA patent/CN110168659A/en active Pending
- 2017-11-09 JP JP2019546763A patent/JP7079790B2/en active Active
-
2022
- 2022-05-23 JP JP2022083889A patent/JP7355415B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2022119871A (en) | 2022-08-17 |
IL266481B1 (en) | 2024-03-01 |
JP7079790B2 (en) | 2022-06-02 |
KR102579786B1 (en) | 2023-09-15 |
CA3042279A1 (en) | 2018-05-17 |
JP7355415B2 (en) | 2023-10-03 |
CN110168659A (en) | 2019-08-23 |
IL266481A (en) | 2019-07-31 |
EP3539034A4 (en) | 2021-01-13 |
JP2020514888A (en) | 2020-05-21 |
WO2018089584A1 (en) | 2018-05-17 |
KR20190077093A (en) | 2019-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10902953B2 (en) | Clinical outcome tracking and analysis | |
US9734291B2 (en) | CNA-guided care for improving clinical outcomes and decreasing total cost of care | |
US9646135B2 (en) | Clinical outcome tracking and analysis | |
US8731966B2 (en) | Systems and methods for real-time data ingestion to a clinical analytics platform to generate a heat map | |
JP7355415B2 (en) | CNA-guided care to improve clinical outcomes and reduce total treatment costs | |
US20160098520A1 (en) | Healthcare utilization visualization | |
Lublóy et al. | Formal professional relationships between general practitioners and specialists in shared care: possible associations with patient health and pharmacy costs | |
JP2020514888A5 (en) | ||
US20210082573A1 (en) | Clinical outcome tracking and analysis systems and methods employing provisional nodal addresses relevant to treatment and refined nodal addresses relevant to prognosis-related expected outcome and risk assessment | |
Somanchi et al. | To predict or not to predict: The case of the emergency department | |
Crump et al. | Closing the digital health evidence gap: development of a predictive score to maximize patient outcomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190522 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40014652 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: G06F0019000000 Ipc: G16H0040200000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201215 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G16H 40/20 20180101AFI20201209BHEP Ipc: G16H 50/70 20180101ALI20201209BHEP Ipc: G06Q 10/10 20120101ALI20201209BHEP |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: COTA, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231128 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: COTA, INC. |